| Symbol | LBRX |
|---|---|
| Name | LB PHARMACEUTICALS INC |
| Sector | UNDEFINED |
| Region | North America |
| Industry | Pharmaceutical Preparations |
| Address | United States |
| Telephone | 917-450-6581 |
| Fax | — |
| — | |
| Website | — |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001691082 |
| Description |
(10% Negative) LB PHARMACEUTICALS INC (LBRX) Reports Q3 2026 Financial Results
Read moreLB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Read moreNew Form 424B3 - LB PHARMACEUTICALS INC <b>Filed:</b> 2026-08-11 <b>AccNo:</b> 0001193125-26-343542 <b>Size:</b> 3 MB
Read moreDeep Track Biotechnology Master Fund, Ltd. 🟢 acquired 192.3K shares (2 derivative) of LB PHARMACEUTICALS INC (LBRX) at $0.00 Transaction Date: Jul 30, 2026 | Filing ID: 331058
Read more(10% Negative) LB PHARMACEUTICALS INC (LBRX) Announces Delay in price Trials for such pre-funded warrant Due to Regulatory Process, Manufacturing Considerations, Safety Review
Read moreNew Form 424B3 - LB PHARMACEUTICALS INC <b>Filed:</b> 2026-07-29 <b>AccNo:</b> 0001193125-26-322276 <b>Size:</b> 44 KB
Read more(10% Negative) LB PHARMACEUTICALS INC (LBRX) Announces Delay in sites Trials for schizophrenia Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment
Read moreLB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in Schizophrenia
Read moreNew Form 424B3 - LB PHARMACEUTICALS INC <b>Filed:</b> 2026-07-22 <b>AccNo:</b> 0001193125-26-311394 <b>Size:</b> 29 KB
Read more